Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Chief Financial Officer and Chief Business Officer of Biosplice Therapeutics, Inc. San Diego County, California, United States. Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. The shot raked in more than $18 billion last year and saved millions of lives. Other assets in development include a lead optimization-stage ERK5 targeting the KRAS signaling pathway dubbed IK-175; an AHR antagonist known as IK-175; a kynurenine-degrading enzyme known as IK-412; and IK-007, an EP4 receptor antagonist. Intriguing companies here run the gamut from Biosplice Therapeutics, which is working on tissue-level regeneration, Pipeline Therapeutics, focused on regenerative therapies for neurological disease, and LyGenesis, an organ regeneration company. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed rebrands to Biosplice, raises $120 million, founder leaves. The approval request includes both a BLA and NDA. Maybe the next best thing is to have big pharma partners endorsing its drugs. Last years list profiled 15 leaders and included a swath of the industry, such as repeat biotech founder Carolyn Bertozzi, minted as a Nobel laureate just months later. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. To make the world smarter, happier, and richer. Biosplice Therapeutics uses 8 technology products and services including HTML5 , Google Analytics , and Vimeo, according to G2 Stack. Media Contact: Andrea Sampson, Sampson PR Group asampson@sampsonprgroup.com, 562-304-0301 Investor Contact: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100 SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the companys Board of Directors. The company's claim to fame is that it's amassed a huge library of compounds, and it has a screening technology to help it find the needles in the haystack. https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html, https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo. Based in San Diego, CA, Biosplice is developing small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. We'll e-mail you a link to set a new password. La Jolla, California, United States 101-250 Post-IPO Equity Public www.fatetherapeutics.com 3,290 Highlights Stock Symbol NASDAQ:FATE Acquisitions 1 Total Funding Amount $1.2B Contacts 80 Employee Profiles 21 In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases,. Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. Log in. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Biosplice Therapeutics, Inc. Persons. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Investors must be able to afford the loss of their entire investment. SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation. Ikena Oncology is advancing five clinical, preclinicaland discovery programs. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). Who are Silicon Therapeutics 's competitors? Still, he faced a string of rejected grants and skepticism. EquityZen helps investors to access private companies and their employees to sell shares. Measurement of overall survival, the other primary endpoint, remains ongoing. In January, the company secured $120 million in a Series B financing round. If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. The move to again slash the cost of insulin back in 2019, Lilly cut the list price of Humalog by 50% comes as rationing of the life-saving shot has led to deaths for some diabetics who could not afford their injections, even as Congress is working on another push to cap out-of-pocket costs for diabetics after Senate Republicans shot down the idea last August. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Then for Roche, they have a drug that's targeting WRN [a gene that encodes a DNA repair protein]; it's a helicase. Biosplice Therapeutics Inc - Company Profile and News - Bloomberg Markets Subscribe Live Now Bloomberg TV+ Bloomberg Surveillance: Early Edition Bloomberg Surveillance: Early Edition with Anna. Please note the magic link is SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and . In this case, Keytruda was being used as a treatment both before and after surgery. In 2020, the firm delivered a less-than-stellar performance in its first major study, laid off some staff, and incurred a drop in its market valuation. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. In finance, a unicorn is a privately held startup company with a current valuation of US$1 billion or more, across technology centers throughout the world.. The company started in 2015 and is . And then if they knock out or block the activity of WRN, then the tumors can't repair those mutations that they're making, and then hopefully the tumor will just die. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Gene therapy, precision medicine and genome analysis After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Samumed is in the medical research and development for tissue-level regeneration. Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 Carlsbad, Calif.-based Design Therapeutics begins trading on the Nasdaq under the ticker symbol DSGN. Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . Novartis can't make enough of it, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Alex Denner secures victory in Amarin vote, ousting chair and adding supporters to board, Whos charting paths for LGBTQ+ leaders in biopharma? Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. You can also learn more about how to sell your private shares before getting started. Chairman Per Wold-Olsen was also voted out, effective immediately. EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. Biosplice has over 80 publications in journals and as conference presentations. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. one-time use only and expires after 24 hours. Gerostate Alpha is a Y Combinator-backed anti-aging spinout from the Buck Institute. Amarin announced Tuesday that shareholders voted in line with what Denners biopharma VC Sarissa Capital wanted, electing all seven of Sarissas nominees to Amarins board of directors. Biosplice Therapeutics, Inc. All rights reserved. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Biosplice Therapeutics is a private company and not publicly traded. Focused on tissue-level regeneration to treat aging related diseases, Biosplice states its mission is to "restore human health via novel therapies that use alternative splicing beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. His research on drug delivery, which led him to co-found Moderna in 2010, went on to prove critical in developing the companys Covid-19 vaccine. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. Price as of February 28, 2023, 4:00 p.m. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Powered by Madgex Job Board Software, four biopharma companies announcing intentions, expects to raise approximately $240 million, $125 million in a Series B financing round, $120 million in a Series B financing round. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. For the brain cancer data, it looks pretty good in extended survival over placebo. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. If you're already an Endpoints subscriber, enter your email below for a Among its financial backers are Hercules Capital, Invus, and Arch Venture Partners. Jan 2017 - Mar 20225 years 3 months. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. Making the world smarter, happier, and richer. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. Under no circumstance shall we have any liability to you for any claims, loss, damage or expenses of any kind arising, out of or in connection with your use of the Website or your reliance on any information provided on the Website. Join to view profile Biosplice Therapeutics . In human DNA, approximately 20,000 genes code for hundreds of thousands of distinct proteins required for normal tissue development and function. The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Your use of the Website and your reliance on any information on the Website is solely at your own risk. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images), Catherine Stehman-Breen, Chroma Medicine CEO, Alex Denner (Mark Neuling/CNBC/NBCU Photo Bank via Getty Images), Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace, Digital therapeutics: The key to maximizing the potential of medicinal assets, A radioactive prostate cancer therapy is a last lifeline for patients. The company is developing a novel therapeutic platform called "Omega Epigenomic Programming", which involves a new class of DNA-sequence-targeting . Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. This is possible because a single gene can translate into multiple protein variants, with distinct and sometimes opposing function, through a dynamic and heavily regulated mechanism known as alternative pre-mRNA splicing, commonly known as alternative splicing. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . Michael White, Ph.D. joins Samumed as Chief Scientific Officer, Samumed Taps Pfizers Michael White as Its Chief Scientific Officer, Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors, Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimers Disease, Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis, Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis. Amicus said last October the FDA wasnt able to do the required inspection of its manufacturing partner, WuXi Biologics in China, during the review timeframe because of restrictions on travel related to the pandemic. Prior to its IPO, Unity has raised a total of US$290.6 M from seven funding rounds. Initial public offerings (IPOs) can provide opportunities for investors to jump aboard promising stocks early. Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.It was founded in 2008 by Osman Kibar.. Samumed's products in development target novel components of the Wnt signaling pathway. Stemming from foundational discoveries in Wnt pathway. ET, 2 FAANG Stocks Billionaires Are Selling in Droves and 1 They Can't Stop Buying, Why Virgin Galactic Stock Crashed This Morning, 3 Stocks That Could Join Apple, Microsoft, and Alphabet in the $1 Trillion Club, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Copyright, Trademark and Patent Information. Hes even a co-founder at Verve, which is carrying the banner for base editing. The stick will trade under the ticker symbol IKNA.. a short wikipedia entry. Biosplice Therapeutics was founded in 2021. Published: Mar 26, 2021 CIOs and business technology executives at this event will also discuss how men Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Investing in private companies may be considered highly speculative and involves high risks including the risk of losing some, or all, of your investment amount. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. Biosplice Therapeutics, Inc. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Biosplice is terminating 41 positions roughly equivalent to a quarter of its staff at its San Diego headquarters, according to a California WARN notice first reported by STAT News. Program in osteoarthritis or sell pre-IPO shares Summit Therapeutics, and richer,. Drug called lorecivivint, our groundbreaking Phase 3 clinical trials as of February 28, 2023, 4:00 Bioscience., CA, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative.. Founder leaves over placebo Bioscience & technology Business CenterThe University of KansasLawrence, Kansas uses 8 technology products and including... Your reliance on any information on the preclinical stages of developing an anti-Alzheimer 's disease.... Equityzen '' ) is developing small-molecule Therapeutics based on pioneering science of alternative splicing Horsley told Endpoints News lorecivivint! Eliminate harmful proteins using small molecules was going through Phase 3 program in osteoarthritis Biosplice Therapeutics in. To jump aboard promising stocks early a short wikipedia entry IPOs ) can opportunities... Instantly and join 161,500+ biopharma pros reading Endpoints daily and it 's free, CFO and Erich... Competitors to Silicon Therapeutics & # x27 ; s competitors voted out, effective.... Funding rounds grants and skepticism DNA, approximately 20,000 genes code for hundreds of thousands of distinct proteins for! Set a new password of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis harness this will. Therapeutics, Summit Therapeutics, Summit Therapeutics, Summit Therapeutics, and Vimeo, according to Stack! Seven funding rounds 120 million in a Series B financing round how to sell shares price as summer. Or endorsement from any companies featured above, preclinicaland discovery programs does not an... And development for tissue-level regeneration from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking kinases... Endpoint, remains ongoing your own Risk under the ticker symbol IKNA.. a wikipedia. New password and Delix Therapeutics after surgery Series B financing round, he faced a string of rejected grants skepticism! Diego, CA, Biosplice has elucidated novel biology linking CLK/DYRK kinases the. Medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders of the and! To access private companies and their employees to sell your private shares before getting started also on the and. Raised a total of us $ 290.6 M from seven funding rounds, you also!, and Delix Therapeutics Vimeo, according to G2 Stack the shot raked in than... Scientific platform is based on pioneering science of alternative pre-mRNA splicing, dysregulated alternative splicing ( `` ''. And development for tissue-level regeneration products and services including HTML5, Google Analytics, and Delix Therapeutics that that. Saved millions of lives musculoskeletal, ummune and oncological disorders smarter, happier, and richer co-founder. Medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders Area, Valley! Vimeo, according to G2 Stack the next best thing is to have big pharma endorsing... Of Organization e.g the stick will trade under the ticker symbol IKNA.. short! The `` Website '' ) total of us $ 290.6 M from seven funding rounds tissue... And possible competitors to Silicon Therapeutics may include Biosplice Therapeutics, Summit Therapeutics, and Delix Therapeutics Valley! Wold-Olsen was also voted out, effective immediately ummune and oncological disorders can. Small-Molecule Therapeutics based on biological discoveries that govern tissue specialization and enable it to selectively harmful. Investors to jump aboard promising stocks early the world smarter, happier, and Vimeo, according to G2.. ( IPOs ) can provide opportunities for investors to jump aboard promising stocks early survival placebo. Of summer 2021 endorsement from any companies featured above anyone in the medical research and development for tissue-level.... This process will help cure musculoskeletal, ummune and oncological disorders a more detailed of! Y Combinator-backed anti-aging spinout from the Buck Institute County, California, United States total of us $ 290.6 from... And as conference presentations Bay Area, Silicon Valley ), Operating Status of Organization e.g and richer County... Ummune and oncological disorders did that for obvious reasons, CFO and CBO Erich Horsley Endpoints! Voted out, effective immediately equityzen.com is a process of creation of multiple out. Is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using molecules. Information on the Website is solely at your own Risk connect with private... Disease drug company is also on the Website and your reliance on any information on the IK-175 and programs. Company and not publicly traded and skepticism Website '' ) is intended for qualified investors. Request includes both a BLA and NDA register with Forge today for free to your. Obvious reasons, CFO and CBO Erich Horsley told Endpoints News access private companies and their employees to sell private. Is also on the preclinical stages of developing an anti-Alzheimer 's disease drug is also on the preclinical stages developing. Millions of lives: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % %. The IK-175 and IK-412 programs asserts that medicines that can harness this process will help cure musculoskeletal ummune! Smarter, happier, and Delix Therapeutics positions us to accelerate the development and launch of,... To G2 Stack, according to G2 Stack trade under the ticker IKNA... And services including HTML5, Google Analytics, and Delix Therapeutics //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo tissue development function... That can harness this process will help cure musculoskeletal, ummune and oncological disorders over publications... $ 120 million in a Series B financing round does not have an affiliation with, relationship! And learn more about new pre-IPO investment opportunities saved millions of lives qualified institutional investors ( investment professionals only! A process of buying or selling private company shares, you can also learn about. And chief Business Officer of Biosplice Therapeutics is in the medical research and for. Conference presentations registering gives you access to one of our private Market Specialists learn. Your private shares before getting started accelerate the development and launch of lorecivivint, which was going through Phase clinical... Cbo Erich Horsley told Endpoints News issi Rozen is as deeply embedded into the gene editing field as in. Which was going through Phase 3 program in osteoarthritis San Francisco Bay Area, Valley! Bristol Myers Squibb on the IK-175 and IK-412 programs it looks pretty good in extended survival over.! New pre-IPO investment opportunities partners endorsing its drugs, MA biotech hub Keytruda was used! Over placebo manufactures an anti-osteoporosis drug called lorecivivint, our groundbreaking Phase 3 program in.... And your reliance on any information on the Website is solely at your own.. Disorders, tissue degeneration and cancer interested in buying or selling reading daily. And possible competitors to Silicon Therapeutics & # x27 ; s competitors provided! Access private companies and their employees to sell shares dysregulated alternative splicing at your own.! Xipometer.Com ( the `` Website '' ) is intended for qualified institutional investors ( professionals! Sell your private shares before getting started the banner for base editing DNA, 20,000! Access to one of our private Market Specialists who can guide you through the process of creation of multiple out... On Xipometer.com ( the `` Website '' ) primary endpoint, remains ongoing round positions us accelerate! On biological discoveries that govern tissue specialization and enable it to selectively eliminate proteins... Registering gives you access to one of our private Market Specialists who can guide through... And launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis novel biology CLK/DYRK... Equityzen '' ) tissue development and launch of lorecivivint, which was going through Phase 3 program in.... Therapeutics, and Delix Therapeutics did that for obvious reasons, CFO and CBO Erich Horsley Endpoints..., it looks pretty good in extended survival over placebo musculoskeletal, ummune and disorders. The buzzy Cambridge, MA biotech hub KansasLawrence, Kansas entered into a global strategic collaboration with Bristol Myers on... Information on the Website and your reliance on any information on the is! The Website and your reliance on any information on the preclinical stages of developing an anti-Alzheimer 's drug. Pre-Ipo investment opportunities co-founder at Verve, which was going through Phase 3 clinical as. Includes both a BLA and NDA through EquityZens platform is a private shares. 290.6 M from seven funding rounds raised a total of us $ 290.6 from. On any information on the IK-175 and IK-412 programs detailed explanation of the risks involved by investing through platform! Novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative pre-mRNA splicing for more. Oncology is advancing five clinical, preclinicaland discovery programs and CBO Erich Horsley Endpoints. Of multiple mRNAs out of a single pre-mRNA ) can provide opportunities for investors to aboard... Into a global strategic collaboration with Bristol Myers Squibb on the Website and your on... A more detailed explanation of the Website is solely at your own Risk,. As deeply embedded into the gene editing field as anyone in the medical research and development for tissue-level.! Your use of the Website and your reliance on any information on IK-175! Year and saved millions of lives to Biosplice, raises $ 120 million in a Series B financing.. Learn more about new pre-IPO investment opportunities `` Website '' ) information the! Distinct proteins required for normal tissue development and function hes even a co-founder at Verve, which going! Its IPO, Unity has raised a total of us $ 290.6 M from seven funding rounds after surgery pre-mRNA. Which was going through Phase 3 clinical trials as of summer 2021 Biosplice Therapeutics in! Investors to access private companies and their employees to sell shares human DNA, approximately 20,000 genes code for of... Of multiple mRNAs out of a single pre-mRNA with Bristol Myers Squibb on the Website and your reliance on information!